{{Rsnum
|rsid=3789068
|Gene=BCL2L11
|Chromosome=2
|position=111151670
|Orientation=minus
|GMAF=0.3962
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=BCL2L11
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 21.2 | 51.3 | 27.4
| HCB | 22.6 | 54.0 | 23.4
| JPT | 15.0 | 46.9 | 38.1
| YRI | 7.5 | 44.9 | 47.6
| ASW | 7.0 | 36.8 | 56.1
| CHB | 22.6 | 54.0 | 23.4
| CHD | 24.1 | 44.4 | 31.5
| GIH | 1.0 | 39.6 | 59.4
| LWK | 6.4 | 40.0 | 53.6
| MEX | 3.4 | 41.4 | 55.2
| MKK | 4.5 | 26.9 | 68.6
| TSI | 16.7 | 45.1 | 38.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=19336552
|Title=Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development.
|OA=1
}}

{{PMID Auto
|PMID=23047821
|Title=PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}